NASDAQ$RNA

Atrium Therapeutics Inc · Q1 2024 earnings

Q1 2024 earnings ·

Briefing

RNA Q1 2024 — $2.4M revenue, 0.79 EPS

Any of these actions could materially harm the Company’s business, results of operations and future prospects. Atrium Therapeutics Inc reported Q1 2024 results. Diluted EPS came in at $0.79. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $2.4M.
  • Diluted EPS: $0.79.
  • Filed on Form 10-Q (accession 0001599901-24-000073).

Headline financials

Total Revenue

$3.54M

Previous: $2.23M+58.7%
EPS

-$0.79

Previous: -$0.74-6.8%
Capital Expenditures

-$915K

Previous: -$1.82M+49.7%
Free Cash Flow

-$69.8M

Previous: -$54.2M-28.7%
Net Income

-$68.9M

Previous: -$52.4M-31.4%
Operating Income

-$77.2M

Previous: -$57.6M-34.0%

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$3.54M

Q1 2024+58.7%vs Q1 2023
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro